Characteristics of patients with stage I-II NLPHL
| Parameter . | Total (n = 559) . | RT (n = 257) . | CMT (n = 184)* . | CT (n = 47)† . | Observation (n = 37) . | Rituximab and RT (n = 19) . | Rituximab alone (n = 15) . | P‡ . |
|---|---|---|---|---|---|---|---|---|
| n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | ||
| Age at diagnosis | ||||||||
| Median (years) | 39 | 42 | 36 | 36 | 43 | 33 | 57 | .01 |
| IQR | 27-52 | 29-53 | 25-49 | 25-48 | 22-59 | 21-42 | 31-72 | |
| Range | 16-90 | 17-90 | 16-75 | 17-76 | 16-81 | 18-65 | 16-82 | |
| Sex | ||||||||
| Male | 404 (72.3) | 187 (72.8) | 140 (76.1) | 30 (63.8) | 24 (64.9) | 15 (78.9) | 8 (53.3) | .21 |
| Female | 155 (27.7) | 70 (27.2) | 44 (23.9) | 17 (36.2) | 13 (35.1) | 4 (21.1) | 7 (46.7) | |
| ECOG PS | ||||||||
| 0-1 | 486 (86.9) | 205 (79.8) | 173 (94.0) | 44 (93.6) | 34 (91.9) | 18 (94.7) | 12 (80.0) | .002 |
| >1 | 8 (6.0) | 2 (0.8) | 2 (1.1) | 0 (0.0) | 2 (5.4) | 0 (0.0) | 2 (13.3) | |
| Unreported | 65 (11.6) | 50 (19.4) | 9 (4.9) | 3 (6.4) | 1 (2.7) | 1 (5.3) | 1 (6.7) | |
| Stage | ||||||||
| Stage I | 307 (54.9) | 175 (68.1) | 77 (41.8) | 11 (23.4) | 32 (86.5) | 9 (47.4) | 3 (20.0) | <.0001 |
| Extranodal | 12 (2.1) | 3 (1.2) | 4 (2.2) | 2 (4.3) | 3 (8.1) | 0 (0.0) | 0 (0.0) | |
| B symptoms | 13 (2.3) | 6 (2.3) | 2 (1.1) | 4 (8.5) | 1 (2.7) | 0 (0.0) | 0 (0.0) | |
| Stage II | 252 (45.1) | 82 (31.9) | 107 (58.2) | 36 (76.6) | 5 (13.5) | 10 (52.6) | 12 (80.0) | |
| Extranodal | 20 (3.6) | 9 (3.5) | 8 (4.3) | 1 (2.1) | 1 (2.7) | 0 (0.0) | 1 (6.7) | |
| B symptoms | 25 (4.5) | 8 (3.1) | 11 (6.0) | 4 (8.5) | 0 (0.0) | 1 (5.3) | 1 (6.7) | |
| Spleen | 4 (0.7) | 2 (0.8) | 2 (1.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Disease location | ||||||||
| Above diaphragm | 439 (78.5) | 206 (80.2) | 151 (82.1) | 31 (66.0) | 25 (67.6) | 15 (78.9) | 11 (73.3) | .17 |
| Below diaphragm | 116 (20.8) | 50 (19.5) | 32 (17.4) | 14 (29.8) | 12 (32.4) | 4 (21.1) | 4 (26.7) | |
| Unknown | 4 (0.7) | 1 (0.4) | 1 (0.5) | 2 (4.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Immunoarchitecture | ||||||||
| A/B Typical | 166 (29.7) | 86 (33.5) | 59 (32.1) | 10 (21.3) | 6 (16.2) | 3 (15.8) | 2 (13.3) | .01 |
| C/D/E/F Variant | 43 (7.7) | 14 (5.4) | 17 (9.2) | 3 (6.4) | 3 (8.1) | 1 (5.3) | 5 (33.3) | |
| Unknown | 350 (62.6) | 157 (61.1) | 108 (58.7) | 34 (72.3) | 28 (75.7) | 15 (78.9) | 8 (53.3) | |
| Follow up, years | ||||||||
| Median | 5.5 | 5.4 | 5.9 | 5.0 | 4.1 | 3.8 | 6.3 | .02 |
| IQR | 3.1-10.1 | 3.0-10.1 | 3.8-10.8 | 2.8-8.6 | 1.9-5.8 | 2.4-10.9 | 3.1-7.4 | |
| GHSG clinical criteria | ||||||||
| Favorable | 473 (84.6) | 234 (91.1) | 152 (82.6) | 31 (66.0) | 35 (94.6) | 13 (68.4) | 8 (53.3) | <.0001 |
| Unfavorable | 77 (13.8) | 21 (8.2) | 27 (14.7) | 14 (29.8) | 2 (5.4) | 6 (31.6) | 7 (46.7) | |
| Unknown | 9 (1.6) | 2 (0.8) | 5 (2.7) | 2 (4.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Treatment dates (range) | 1995-2018 | 1995-2018 | 1995-2018 | 1996-2017 | 2003-2018 | 2002-2017 | 2000-2018 |
| Parameter . | Total (n = 559) . | RT (n = 257) . | CMT (n = 184)* . | CT (n = 47)† . | Observation (n = 37) . | Rituximab and RT (n = 19) . | Rituximab alone (n = 15) . | P‡ . |
|---|---|---|---|---|---|---|---|---|
| n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | n (%) . | ||
| Age at diagnosis | ||||||||
| Median (years) | 39 | 42 | 36 | 36 | 43 | 33 | 57 | .01 |
| IQR | 27-52 | 29-53 | 25-49 | 25-48 | 22-59 | 21-42 | 31-72 | |
| Range | 16-90 | 17-90 | 16-75 | 17-76 | 16-81 | 18-65 | 16-82 | |
| Sex | ||||||||
| Male | 404 (72.3) | 187 (72.8) | 140 (76.1) | 30 (63.8) | 24 (64.9) | 15 (78.9) | 8 (53.3) | .21 |
| Female | 155 (27.7) | 70 (27.2) | 44 (23.9) | 17 (36.2) | 13 (35.1) | 4 (21.1) | 7 (46.7) | |
| ECOG PS | ||||||||
| 0-1 | 486 (86.9) | 205 (79.8) | 173 (94.0) | 44 (93.6) | 34 (91.9) | 18 (94.7) | 12 (80.0) | .002 |
| >1 | 8 (6.0) | 2 (0.8) | 2 (1.1) | 0 (0.0) | 2 (5.4) | 0 (0.0) | 2 (13.3) | |
| Unreported | 65 (11.6) | 50 (19.4) | 9 (4.9) | 3 (6.4) | 1 (2.7) | 1 (5.3) | 1 (6.7) | |
| Stage | ||||||||
| Stage I | 307 (54.9) | 175 (68.1) | 77 (41.8) | 11 (23.4) | 32 (86.5) | 9 (47.4) | 3 (20.0) | <.0001 |
| Extranodal | 12 (2.1) | 3 (1.2) | 4 (2.2) | 2 (4.3) | 3 (8.1) | 0 (0.0) | 0 (0.0) | |
| B symptoms | 13 (2.3) | 6 (2.3) | 2 (1.1) | 4 (8.5) | 1 (2.7) | 0 (0.0) | 0 (0.0) | |
| Stage II | 252 (45.1) | 82 (31.9) | 107 (58.2) | 36 (76.6) | 5 (13.5) | 10 (52.6) | 12 (80.0) | |
| Extranodal | 20 (3.6) | 9 (3.5) | 8 (4.3) | 1 (2.1) | 1 (2.7) | 0 (0.0) | 1 (6.7) | |
| B symptoms | 25 (4.5) | 8 (3.1) | 11 (6.0) | 4 (8.5) | 0 (0.0) | 1 (5.3) | 1 (6.7) | |
| Spleen | 4 (0.7) | 2 (0.8) | 2 (1.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Disease location | ||||||||
| Above diaphragm | 439 (78.5) | 206 (80.2) | 151 (82.1) | 31 (66.0) | 25 (67.6) | 15 (78.9) | 11 (73.3) | .17 |
| Below diaphragm | 116 (20.8) | 50 (19.5) | 32 (17.4) | 14 (29.8) | 12 (32.4) | 4 (21.1) | 4 (26.7) | |
| Unknown | 4 (0.7) | 1 (0.4) | 1 (0.5) | 2 (4.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Immunoarchitecture | ||||||||
| A/B Typical | 166 (29.7) | 86 (33.5) | 59 (32.1) | 10 (21.3) | 6 (16.2) | 3 (15.8) | 2 (13.3) | .01 |
| C/D/E/F Variant | 43 (7.7) | 14 (5.4) | 17 (9.2) | 3 (6.4) | 3 (8.1) | 1 (5.3) | 5 (33.3) | |
| Unknown | 350 (62.6) | 157 (61.1) | 108 (58.7) | 34 (72.3) | 28 (75.7) | 15 (78.9) | 8 (53.3) | |
| Follow up, years | ||||||||
| Median | 5.5 | 5.4 | 5.9 | 5.0 | 4.1 | 3.8 | 6.3 | .02 |
| IQR | 3.1-10.1 | 3.0-10.1 | 3.8-10.8 | 2.8-8.6 | 1.9-5.8 | 2.4-10.9 | 3.1-7.4 | |
| GHSG clinical criteria | ||||||||
| Favorable | 473 (84.6) | 234 (91.1) | 152 (82.6) | 31 (66.0) | 35 (94.6) | 13 (68.4) | 8 (53.3) | <.0001 |
| Unfavorable | 77 (13.8) | 21 (8.2) | 27 (14.7) | 14 (29.8) | 2 (5.4) | 6 (31.6) | 7 (46.7) | |
| Unknown | 9 (1.6) | 2 (0.8) | 5 (2.7) | 2 (4.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Treatment dates (range) | 1995-2018 | 1995-2018 | 1995-2018 | 1996-2017 | 2003-2018 | 2002-2017 | 2000-2018 |
PS, performance score.
CMT included rituximab (n = 48; 26.1%).
CT included rituximab (n = 17; 36.2%).
P-value for between-group comparisons calculated for continuous variables with analysis of variance and categorical variables with χ2 test (excluding unreported/unknown for ECOG PS, immunoarchitecture and GHSG risk group).